Thyroid receptor: roles in cancer

Trends in Endocrinology and Metabolism

Volumn 20, Issue 7, 2009, Pages 318-324

  Aranda, Ana ^a   Martínez Iglesias, Olaia ^a   Ruiz Llorente, Lidia ^a   García Carpizo, Verónica ^a   Zambrano, Alberto ^a  

^a CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; CYCLOOXYGENASE 2; INHIBITOR OF DIFFERENTIATION 1; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR RECEPTOR COREPRESSOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN C JUN; PROTEIN KINASE B; RAS PROTEIN; RETINOIC ACID RECEPTOR; S6 KINASE; SCATTER FACTOR RECEPTOR; SECURIN; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; TRANSCRIPTION FACTOR AP 1; WNT PROTEIN;

BREAST CANCER; CARCINOGENESIS; CARCINOGENICITY; GENE MUTATION; GENE SILENCING; HUMAN; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; LIVER CANCER; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; TUMOR GROWTH;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBA; HUMANS; MICE; NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; THYROID DISEASES;

EID: 68149111051     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.03.011     Document Type: Review

References (69)

1. Flamant F., et al. International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev. 58 (2006) 705-711
2. Yen P.M., et al. Thyroid hormone action at the cellular, genomic and target gene levels. Mol. Cell. Endocrinol. 246 (2006) 121-127
3. Aranda A., and Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81 (2001) 1269-1304
4. Lazar M.A. Nuclear receptor corepressors. Nucl. Recept. Signal. 1 (2003) e001
5. Privalsky M.L. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu. Rev. Physiol. 66 (2004) 315-360
6. Gronemeyer H., et al. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3 (2004) 950-964
7. Rosenfeld M.G., et al. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 (2006) 1405-1428
8. Han S.J., et al. Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol. Metab. 20 (2009) 8-15
9. Wang D., et al. Negative regulation of TSH{alpha} target gene by thyroid hormone involves histone acetylation and corepressor complex dissociation. Mol. Endocrinol. 23 (2009) 600-609
10. Mendez-Pertuz M., et al. The thyroid hormone receptor antagonizes CREB-mediated transcription. EMBO J. 22 (2003) 3102-3112
11. Rogatsky I., et al. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20 (2001) 6071-6083
12. Bergh J.J., et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146 (2005) 2864-2871
13. Furuya F., et al. Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids 74 (2009) 628-634
14. Hiroi Y., et al. Rapid nongenomic actions of thyroid hormone. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14104-14109
15. Storey N.M., et al. Rapid signaling at the plasma membrane by a nuclear receptor for thyroid hormone. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5197-5201
16. Davis P.J., et al. Mechanisms of nongenomic actions of thyroid hormone. Front. Neuroendocrinol. 29 (2008) 211-218
17. Yamauchi M., et al. Thyroid hormone activates adenosine 5′-monophosphate-activated protein kinase via intracellular calcium mobilization and activation of calcium/calmodulin-dependent protein kinase kinase-beta. Mol. Endocrinol. 22 (2008) 893-903
18. Rietveld L.E., et al. Avian erythroleukemia: a model for corepressor function in cancer. Oncogene 20 (2001) 3100-3109
19. Wolffe A.P., et al. Thyroid hormone receptor, v-ErbA, and chromatin. Vitam. Horm. 58 (2000) 449-492
20. Lee S., and Privalsky M.L. Multiple mutations contribute to repression by the v-Erb A oncoprotein. Oncogene 24 (2005) 6737-6752
21. Bresson C., et al. Large-scale analysis by SAGE reveals new mechanisms of v-erbA oncogene action. BMC Genomics 8 (2007) 390
22. Zubkova I., and Subauste J.S. V-erba homodimers mediate the potent dominant negative activity of v-erba on everted repeats. Mol. Biol. Rep. 31 (2004) 131-137
23. Bonamy G.M., et al. Cancer promoted by the oncoprotein v-ErbA may be due to subcellular mislocalization of nuclear receptors. Mol. Endocrinol. 19 (2005) 1213-1230
24. Bonamy G.M., and Allison L.A. Oncogenic conversion of the thyroid hormone receptor by altered nuclear transport. Nucl. Recept. Signal. 4 (2006) e008
25. Gonin-Giraud S., et al. Involvement of the TGF-beta and mTOR/p70S6Kinase pathways in the transformation process induced by v-ErbA. Leuk. Res. 32 (2008) 1878-1888
26. Gonzalez-Sancho J.M., et al. Thyroid hormone receptors/THR genes in human cancer. Cancer Lett. 192 (2003) 121-132
27. Conde I., et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann. Oncol. 17 (2006) 60-64
28. Chan I.H., and Privalsky M.L. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene 25 (2006) 3576-3588
29. Horkko T.T., et al. Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int. J. Cancer 118 (2006) 1653-1659
30. Columbano A., et al. The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas. Endocrinology 147 (2006) 3211-3218
31. Columbano A., et al. Triiodothyronine stimulates hepatocyte proliferation in two models of impaired liver regeneration. Cell Prolif. 41 (2008) 521-531
32. Perra A., et al. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology 49 (2009) 1287-1296
33. Ledda-Columbano G.M., et al. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Res. 60 (2000) 603-609
34. Chen R.N., et al. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Res. 68 (2008) 1697-1706
35. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
36. Perez-Juste G., and Aranda A. The cyclin-dependent kinase inhibitor p27(Kip1) is involved in thyroid hormone-mediated neuronal differentiation. J. Biol. Chem. 274 (1999) 5026-5031
37. Perez-Juste G., et al. An element in the region responsible for premature termination of transcription mediates repression of c-myc gene expression by thyroid hormone in neuroblastoma cells. J. Biol. Chem. 275 (2000) 1307-1314
38. Garcia-Silva S., and Aranda A. The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation. Mol. Cell. Biol. 24 (2004) 7514-7523
39. Porlan E., et al. Thyroid hormone receptor-beta (TR beta 1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2. Oncogene 27 (2008) 2795-2800
40. Bungay A., et al. Microarray analysis of mitogenic effects of T3 on the rat liver. J. Gastroenterol. Hepatol. 23 (2008) 1926-1933
41. Pibiri M., et al. Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J. 15 (2001) 1006-1013
42. Barrera-Hernandez G., et al. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity. Endocrinology 140 (1999) 5267-5274
43. Martinez-Iglesias O., et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res. 69 (2009) 501-509
44. Minn A.J., et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6740-6745
45. Minn A.J., et al. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
46. Uchida H., et al. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21 (2006) 161-168
47. Yang X., et al. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int. J. Cancer 118 (2006) 1869-1876
48. Bronnegard M., et al. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue. J. Clin. Endocrinol. Metab. 79 (1994) 384-389
49. Puzianowska-Kuznicka M., et al. Functionally impaired TR mutants are present in thyroid papillary cancer. J. Clin. Endocrinol. Metab. 87 (2002) 1120-1128
50. Rocha A.S., et al. Thyroid hormone receptor beta mutations in the 'hot-spot region' are rare events in thyroid carcinomas. J. Endocrinol. 192 (2007) 83-86
51. Suzuki H., et al. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12 (2002) 963-969
52. Ying H., et al. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J. Clin. Invest. 116 (2006) 2972-2984
53. Guigon C.J., et al. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol. Cell. Biol. 28 (2008) 4598-4608
54. Furuya F., et al. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1780-1785
55. Furuya F., et al. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28 (2007) 2451-2458
56. Guigon C.J., et al. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28 (2009) 509-517
57. Furumoto H., et al. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol. Cell. Biol. 25 (2005) 124-135
58. Lu C., et al. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149 (2008) 3339-3345
59. Ando S., et al. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J. Clin. Endocrinol. Metab. 86 (2001) 5572-5576
60. Safer J.D., et al. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid 11 (2001) 281-291
61. Hall L.C., et al. Effects of thyroid hormones on human breast cancer cell proliferation. J. Steroid Biochem. Mol. Biol. 109 (2008) 57-66
62. Rae M.T., et al. Thyroid hormone signaling in human ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 92 (2007) 322-327
63. Tsui K.H., et al. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 68 (2008) 610-619
64. Plateroti M., et al. Thyroid hormone receptor alpha1 directly controls transcription of the beta-catenin gene in intestinal epithelial cells. Mol. Cell. Biol. 26 (2006) 3204-3214
65. Reddy A., et al. Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin. Gastroenterol. Hepatol. 5 (2007) 118-123
66. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2 (1896) 104-107
67. Silva J.M., et al. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21 (2002) 4307-4316
68. Cristofanilli M., et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer 103 (2005) 1122-1128
69. Hercbergs A.A., et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res. 23 (2003) 617-626